Wayne G. Brisbane
· Assistant Professor of Urology.VerifiedUniversity of California, Los Angeles · Urology
Active 2012–2026
About
Wayne Brisbane, MD, is an Assistant Professor in the Department of Urology at UCLA. His scientific interests include prostate cancer and prostate cancer imaging, with a focus on optimizing medical imaging for risk stratification and treatment guidance. Dr. Brisbane has contributed to research on targeted prostate biopsy, high-resolution ultrasound, magnetic resonance imaging, and prostate cancer risk prediction models. His work aims to improve diagnostic accuracy and treatment outcomes for prostate cancer patients.
Research topics
- Medicine
- Internal medicine
- Radiology
- Computer Science
- Artificial Intelligence
- Nuclear medicine
- Intensive care medicine
- Statistics
- Oncology
- Nursing
- Mathematics
Selected publications
The Journal of Urology · 2026-04-27
articleIP53-21 MICRO-ULTRASOUND AND TISSUE ECHOGENICITY IN PROSTATE CANCER
The Journal of Urology · 2026-04-27
articleSenior authorThe Journal of Urology · 2026-04-27
article1st authorCorrespondingIP37-19 IMPACT OF IRREVERSIBLE ELECTROPORATION ON SEXUAL FUNCTION: AN ANALYSIS OF THE PRESERVE TRIAL
The Journal of Urology · 2026-04-27
articleAI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
BJUI Compass · 2026-02-01
articleOpen accessObjective: This study aimed to evaluate the diagnostic accuracy of artificial intelligence (AI)-enhanced micro-ultrasound (micro-US) for detecting clinically significant prostate cancer (csPCa) in men referred for prostate biopsy. Patients and Methods: We retrospectively analysed 145 men undergoing micro-US-guided biopsy (79 with csPCa, 66 without). Deep features were extracted from 2D micro-US slices using a self-supervised convolutional autoencoder and classified with a random forest model under fivefold cross-validation. Patients were considered csPCa-positive if ≥8 consecutive slices were predicted positive. Diagnostic performance was assessed against biopsy pathology using receiver operating characteristic (ROC) analysis. Results: The AI-micro-US model achieved an area under the ROC curve (AUC) of 0.871. At a fixed threshold, sensitivity was 92.5% and specificity 68.1%, outperforming a clinical model based on prostate-specific antigen (PSA), digital rectal examination (DRE), age, and prostate volume (AUC 0.753; sensitivity 96.2%, specificity 27.3%). Conclusion: AI-enhanced micro-US reduces false positives from conventional screening tools while preserving high sensitivity. It shows promise as a point-of-care alternative to MRI, integrating risk stratification and biopsy guidance into a single platform.
The Journal of Urology · 2026-04-28
articlePURPOSE: Micro-ultrasonography (microUS)-guided biopsy has emerged as an alternative to MRI fusion-guided biopsy for the diagnosis of prostate cancer. This study aimed to externally validate the PRI-MUS (Prostate Risk Identification using Micro-Ultrasound) scoring system for predicting clinically significant prostate cancer (csPCa) using data from the OPTIMUM trial. METHODS: A secondary analysis of the OPTIMUM trial was conducted to evaluate the diagnostic performance of the PRI-MUS scoring system. The analysis included patients who underwent microUS-guided prostate biopsy, with each core assigned a PRI-MUS score. The diagnostic performance of the PRI-MUS scoring system for identifying csPCa was assessed at per-core and per-lesion levels. RESULTS: Three hundred forty-seven patients receiving microUS-guided biopsy were included. At the per-core level, 4590 biopsy cores were analyzed and assigned a PRI-MUS score. When comparing PRI-MUS 1 with 2 vs 3 with 5, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for detecting csPCa were 72%, 74%, 37%, and 93%, respectively. The AUC was 0.78 (95% [CI]: 0.76 to 0.8). At the per-lesion level, 322 lesions were analyzed. When comparing PRI-MUS 1 with 2 vs 3 with 5, the corresponding sensitivity, specificity, PPV, and NPV were 92%, 34%, 55%, and 83%, respectively. The AUC was 0.78 (95% CI: 0.73-0.82). Nineteen high-risk anterior lesions were biopsied, with csPCa detected in 11 (57.8%). CONCLUSIONS: The PRI-MUS scoring system demonstrated high sensitivity and NPV for diagnosing csPCa at both the per-core and per-lesion levels, supporting its validity as a risk-stratification tool for microUS-guided biopsy.
PD04-07 ENHANCING PROSTATE CANCER CARE WITH EDUCATIONAL VIDEOS: A QUALITY IMPROVEMENT INITIATIVE
The Journal of Urology · 2026-04-27
articleSenior authorMicro‐ultrasound tissue echogenicity predicts prostate cancer grade
BJUI Compass · 2026-04-01
articleOpen accessSenior authorAbstract Objectives This study aimed to evaluate the association between lesion echogenicity on micro‐ultrasound (micro‐US) and the presence and grade of prostate cancer. Patients and Methods We prospectively analysed 229 prostate lesions from 181 men undergoing micro‐US‐guided transperineal biopsy at UCLA. Lesions were visually graded as hyperechoic, isoechoic or hypoechoic relative to the central zone, which served as an internal reference due to its consistent tissue characteristics and low malignancy risk. Biopsy targeting was confirmed by visualizing the needle tract within the lesion. The primary outcome was the detection rate of Grade Group (GG) ≥ 2 cancer across echogenicity categories. Secondary analyses included associations with PSA density and MRI‐derived apparent diffusion coefficient (ADC) values, given that ADC is associated with tissue cellularity. Statistical comparisons were performed using chi‐square and Kruskal–Wallis tests, with post hoc pairwise analyses where appropriate. Results GG ≥ 2 cancer detection rates increased with decreasing echogenicity: 22% in hyperechoic, 56.2% in isoechoic and 62.4% in hypoechoic lesions ( p < 0.01). Hypoechoic lesions also exhibited a higher proportion of GG ≥ 3 cancers ( p < 0.05). ADC values declined progressively from hyperechoic to hypoechoic lesions (median: 980, 851 and 751, respectively; p < 0.01), suggesting higher tissue cellularity. Regression analysis demonstrated no meaningful interaction between PRI‐MUS and echogenicity. PSA density did not significantly differ among echogenicity groups. Conclusions Lesion hypoechogenicity on micro‐US is strongly associated with higher grade prostate cancer and lower ADC values, suggesting a link to tissue cellularity. These findings support the incorporation of echogenicity as a diagnostic marker within the micro‐US PRI‐MUS framework, potentially enhancing the accuracy of prostate cancer risk stratification.
The Journal of Urology · 2026-04-27
articleJournal of Clinical Oncology · 2026-03-01
article369 Background: MRI-guided transurethral ultrasound ablation (TULSA) uses MRI to target, monitor, and control thermal ablation of prostate tissue with high intensity directional ultrasound, demonstrating favorable histologic control and preservation of genitourinary function in single-arm studies [1,2]. CAPTAIN (NCT05027477) is a post-market, multi-center randomized controlled trial (RCT) of TULSA vs RARP for intermediate-risk prostate cancer, and is the first such study to meet its enrolment target. Here we compare baseline patient characteristics, treatment parameters, and periprocedural outcomes. Methods: CAPTAIN enrolled men with treatment-naïve, organ-confined, Grade Group 2 or 3 prostate cancer at 23 centers including academic and private clinics in the USA (20), Canada (2), and Finland (1). Patients were randomized 2:1 to TULSA or RARP, without crossover. Endpoints include pad-free urinary continence (EPIC) and erections sufficient for penetration (IIEF Q2) at 1 year, salvage treatment at 3 years, and survival to 10 years. Periprocedural metrics include length of stay, blood loss, catheter time, and 30-day patient diary (EQ-5D-5L, NRS pain score). Results: 211 patients were treated from Jan 2022 to Aug 2025 (70% TULSA, 30% RARP), surpassing the enrolment target of 201. Arms had similar baseline characteristics: median (IQR) age for TULSA vs. RARP was 63 (58–68) vs 65 (60–69) years (p=0.12), PSA was 6.5 (4.9–9.6) vs 7.2 (5.6–9.7) ng/mL (p=0.63), Grade Group 2/3 proportions were 76%/24% vs 77%/23% (p=0.88). RARP involved bilateral, unilateral, or no nerve sparing in 89%, 5.7%, and 5.7% of cases. TULSA ablation plans included whole-gland (68%) and ≥hemi-ablation (32%). Median (IQR) blood loss was lower during TULSA vs RARP: 0 (0–0) vs 100 (100–200) mL (p<0.001). Hospital stay was shorter for TULSA: 0.29 (0.27–0.32) vs 1.24 (1.12–1.36) days (p<0.001). Catheter duration was longer post-TULSA: 13 (11–15) vs 8 (8–10) days (p<0.001). Patients reported lower NRS pain scores after TULSA to post-operative day 6, and less decline in overall health on the EQ-5D-5L 0-100 visual analog scale over 30 days (p<0.05). Fewer patients reported extreme inability on EQ-5D-5L after TULSA vs RARP over the first month for mobility (0% vs 15%), self-care (1% vs 18%), and usual activities (18% vs 38%) (all p<0.05). Conclusions: CAPTAIN is the first multicenter RCT comparing ablation to radical prostate cancer treatment to meet its enrollment target. Early perioperative results from CAPTAIN demonstrate that TULSA had no blood loss or overnight hospitalization, reduced post-procedural pain, and faster return to baseline activities and overall health. Data collection to 1 and 3 years post-treatment continues to readout of the primary safety and oncological outcomes. [1] Klotz et al 2021, JUrol 205(3):769-779. [2] Eggener et al 2024, UrolOnc 42:S83. Clinical trial information: NCT05027477 .
Frequent coauthors
- 24 shared
Leonard S. Marks
- 21 shared
Anthony Sisk
- 20 shared
Adam Kinnaird
University of Alberta
- 20 shared
Alan Priester
- 20 shared
Robert E. Reiter
- 18 shared
Ely Felker
University of California, Los Angeles
- 17 shared
Padraic O’Malley
- 17 shared
Paul L. Crispen
University of Florida
Education
M.D.
Loma Linda University School of Medicine
Awards & honors
- Super Doctors® Southern California Rising Stars, 2026
- Prostate Cancer Foundation - Young Investigator Award
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Wayne G. Brisbane
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup